www.alliancepharma.co.uk
Alliance Pharma plc is a United Kingdom-based pharmaceutical company. The Company is engaged in the development, marketing and distribution of pharmaceutical products. Its brands include Nu-Seals, Forceval, Hydromol, Deltacortril, Symmetrel, Syntocinon, Naseptin, Syntometrine, Synacthen and Slow-K.
Alliance Pharma shareholder Nigel Wray buys 200,000 more shares
Alliance Pharma (AIM: APH) announced that Nigel Wray has bought a further 200,000 shares in the company to take his holding to 24,519,995 shares, or 11.04% of the capital. He is still the group's second largest shareholder behind chief executive John Dawson.
Alliance Pharma (AIM: APH) last month completed the acquisition of Cambridge Laboratories. The deal, which adds 18 new prescription products to Alliance’s portfolio, is expedted to be significantly earnings enhancing in the current financial year. Cambridge’s commercial manager Peter Butterfield has also been appointed to the Alliance Pharma board.
The deal is worth between £14.3m and £16.4m, plus an additional £1.4m for Cambridge’s product inventory.
Back in January, Alliance said it expected to report turnover for the full year to 31 December 2009 of approximately £31 million, an increase of approximately 42% on the previous year.
Shares in Alliance have performed very well over the past six months as the stock’s value almost doubled from below 20 pence to the current 35 pence.
















